Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
2cureX ABFRA:2QE +0.38%37 Net Margin % is -8,850.00% as of Jun. 2025. GuruFocus rates FRA:2QE with a GF Score™ of 37/100. The stock has 3 warning signs investors should review. Among 942 Biotechnology companies, 2cureX AB ranks worse than 95.12% on this metric.
Net margin is calculated as Net Income divided by its Revenue. 2cureX AB's Net Income for the
six
months ended in Jun. 2025 was €-0.18 Mil. 2cureX AB's Revenue for the
six
months ended in Jun. 2025 was €0.00 Mil. Therefore, 2cureX AB's net margin for the quarter that ended in Jun. 2025 was -8,850.00%.
The historical rank and industry rank for 2cureX AB's Net Margin % or its related term are showing as below:
FRA:2QE'
s Net Margin % Range Over the Past 10 Years
Min: -33077.78 Med: -19875.06 Max: -6672.34
Current: -20800
FRA:2QE's Net Margin % is ranked worse than 95.12% of 942
companies
in the Biotechnology industry
Industry Median: -88.295
vs FRA:2QE: -20800.00
2cureX AB (FRA:2QE) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
2cureX AB Net Margin % Related Terms
2cureX AB Net Margin % Historical Data
* Premium members only.
The historical data trend for 2cureX AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2QE vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, 2cureX AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
2cureX AB Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 2cureX AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where 2cureX AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2cureX AB (FRA:2QE) has a Net Margin % of -8,850.00% as of Jun. 2025. Net margin is the ratio of total net income to net sales. View historical data on 2cureX AB and its competitors. According to the industry distribution chart, 2cureX AB ranks #896 out of 942 companies in the Biotechnology industry, placing it in the top 95.1%.
Is 2cureX AB's Net Margin % too high?
2cureX AB's current Net Margin % is -8,850.00%. Based on the distribution chart, 2cureX AB ranks #896 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, 2cureX AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does 2cureX AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 2cureX AB ranks #896 out of 942 companies for Net Margin %. This places 2cureX AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on 2cureX AB and its competitors. 2cureX AB's current Net Margin % is -8,850.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 2cureX AB stock overvalued right now?
2cureX AB (FRA:2QE) has a current Net Margin % of -8,850.00%. The current Net Margin % is -8,850.00%. 2cureX AB's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For 2cureX AB (FRA:2QE), the current Net Margin % is -8,850.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
37GF Score
Get the complete analysis for FRA:2QE
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QE has been successfully added to your 
